OmniAb (US:OABI) — Company Overview, News & Financial Data
OmniAb specializes in developing antibody-based therapeutics, focusing on oncology and immunology through innovative technology.
OmniAb
OmniAb (NASDAQ:OABI) specializes in leveraging its proprietary technology to discover and develop innovative antibody-based therapeutics for a broad range of diseases. The company thrives on a dynamic platform that includes advanced genetic engineering, immunization, and screening technologies designed to address complex therapeutic challenges. OmniAb's operations revolve around partnerships and collaborations with biopharmaceutical entities, with a mission to expedite the journey from discovery to clinical stages. The company's projects span oncology, immunology, and infectious diseases among other areas, showcasing a versatile and potent approach to tackling severe health issues. Objectively, OmniAb aims to harness its cutting-edge technology to push the boundaries of antibody therapy, optimizing efficacy, safety, and accessibility for patients worldwide.
Snapshot
Operations
Products and/or services of OmniAb
- Antibody discovery platform leveraging transgenic animals for developing human therapeutic antibodies with diverse and optimized immune repertoire.
- Humanized rodent models designed to produce a broad diversity of high-affinity human antibodies, facilitating rapid discovery and development of therapeutic candidates.
- Modular OmniRat, OmniMouse, and OmniFlic platforms, offering diverse options for monoclonal antibody development against challenging targets in multiple therapeutic areas.
- OmniChicken platform, providing unique capabilities for generating antibodies with high specificity and affinity, suitable for a variety of therapeutic applications.
- OmniClic, a specialized platform for the generation of bispecific antibodies, enhancing therapeutic potential through targeted dual-action mechanisms.
- Integrated antibody discovery and optimization services, supporting partners from early-stage research through to pre-clinical development.
OmniAb executive team
- Mr. Matthew W. FoehrPresident, CEO & Director
- Mr. Kurt A. GustafsonExecutive VP of Finance & CFO
- Mr. Charles S. Berkman J.D.Chief Legal Officer & Secretary
- Ms. Cia McCaffreyVice President of People & Talent
- Dr. Bill Harriman Ph.D.Senior Vice President of Antibody Discovery
- Dr. Christel Iffland Ph.D.Senior Vice President of Antibody Technologies
- Dr. Yasmina Noubia Abdiche Ph.D.Senior Vice President of Exploratory Research
- Mr. Todd Pettingill C.F.A.Vice President of Business Development & Strategy